Live Breaking News & Updates on Waisman Biomanufacturing

Stay updated with breaking news from Waisman biomanufacturing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Global Induced Pluripotent Stem Cell (iPS Cell) Industry


Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Methods of Commercializing iPSCs are Diverse and Continue to Expand
April 13, 2021 06:13 ET
| Source:
Research and Markets
Research and Markets
Dublin, IRELAND
ResearchAndMarkets.com s offering.
The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.
Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs ....

United States , James Thomson , Takara Bio , Biocat Gmb , Waisman Biomanufacturing , Cellgenix Gmb , Shinya Yamanaka , Masayo Takahashi , Promocell Gmb , Cell Biolabs Inc , Metrion Biosciences Ltd , Categories Of Research Publications , Fate Therapeutics Inc , Beckman Coulter Life Sciences , Pscs Technology , Rd Systems Inc , Bluerock Development Agreement , Takeda Pharmaceutical Co Ltd , Xcell Science Inc , Corning Inc , Thermo Fisher Scientific Inc , Gentarget Inc , Biotechnology Europe Ltd , Stemcell Asc Inc , Lonza Group Ltd , Vistagen Therapeutics Inc ,

Global Induced Pluripotent Stem Cell (iPS Cell) Market Report 2021: In Total, At Least 68 Distinct Market Competitors Now Offer Various Types of iPSC Products, Services, Technologies and Therapies


Share this article
Share this article
ResearchAndMarkets.com s offering.
The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.
Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. ....

United States , James Thomson , Takara Bio , Biocat Gmb , Waisman Biomanufacturing , Cellgenix Gmb , Shinya Yamanaka , Masayo Takahashi , Promocell Gmb , Laura Wood , Cell Biolabs Inc , Metrion Biosciences Ltd , Categories Of Research Publications , Fate Therapeutics Inc , Beckman Coulter Life Sciences , Pscs Technology , Rd Systems Inc , Bluerock Development Agreement , Takeda Pharmaceutical Co Ltd , Office Hours Call , Xcell Science Inc , Corning Inc , Thermo Fisher Scientific Inc , Gentarget Inc , Biotechnology Europe Ltd , Stemcell Asc Inc ,

UMass Medical School-licensed HIV firm wins FDA approval


A biotechnology company working on a vaccine to prevent HIV, whose work is licensed by UMass Medical School in Worcester, has won U.S. Food and Drug Administration approval to advance its clinical work.
The firm, Worcester HIV Vaccine, was approved for the FDA s investigational new drug process for a vaccine that s aimed at preventing the virus that causes AIDS. An early-stage clinical trial is expected to start this month, with a second-phase trial to follow, the medical school said Friday.
Image
Dr. Shan Lu
The potential vaccine is based on discoveries by Dr. Shan Lu, a professor of medicine at UMass Medical School and licensed by the Worcester school. Worcester HIV Vaccine was founded more than two years ago, and the investigational drug approval by the FDA is a major achievement in its development, Yegor Veronin, the firm s COO, said in a statement. ....

United States , Shan Lu , Waisman Biomanufacturing , Yegor Veronin , National Institute Of Allergy , Drug Administration , Umass Medical School In Worcester , Infectious Disease Research Institute In Seattle , Photo Courtesy Umass Medical School , Department Of Health Human Services , Umass Medical School , Us Department Of Health Human Services , Medical School , National Institute , Infectious Diseases , Wisconsin Based Waisman Biomanufacturing , Infectious Disease Research Institute , Human Services , ஒன்றுபட்டது மாநிலங்களில் , ஷான் லு , தேசிய நிறுவனம் ஆஃப் ஒவ்வாமை , உமஸ்ஸ் மருத்துவ பள்ளி இல் வர்ஸெஸ்டர் , தொற்று நோய் ஆராய்ச்சி நிறுவனம் இல் சீட்டில் , புகைப்படம் மரியாதை உமஸ்ஸ் மருத்துவ பள்ளி , துறை ஆஃப் ஆரோக்கியம் மனிதன் சேவைகள் , உமஸ்ஸ் மருத்துவ பள்ளி ,

Global Mesenchymal Stem Cells (MSC) Market Report 2021-2027: Market Competitors areExploring Commercialization Strategies for MSC-Derived Extracellular Vesicles (EVs) and Exosomes


Share this article
Share this article
ResearchAndMarkets.com s offering.
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes.
In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cell types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogeneic transplantation.
MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as th ....

United States , South Korea , Nanoview Biosciences , Biocat Gmb , Waisman Biomanufacturing , Anjarium Biosciences , Stemmatters Biotechnologiae Medicina , Tavec Pharma , Aruna Bio , Codiak Biosciences , Zimmer Biomet , Allogeneic Mscs , Depuy Synthes , Apceth Biopharma Gmb , Laura Wood , Alexerion Biotech Corp , Biovision Inc , Adipomics Inc , Exosome Diagnostics Inc , Nipro Corporation , Nuvasive Inc , Celularity Inc , Osiris Therapeutics Inc , Surgical Inc , Pluristem Therapeutics Inc , Vericel Corporation ,